SEC 13F Intelligence

Managers / Q2 2024 · view latest →

Artia Global Partners LP

CIK 0001937964 · 1 SE 3RD AVENUE, STE 2120, MIAMI, FL, 33131 · 3057101384

Reported Value
$517M
Q2 2024
Positions
46
Filings on Record
15
2019–present window
Filed
Aug 14, 2024
original filing

Summary

Artia Global Partners LP reported $517M in U.S.-listed holdings across 46 positions for Q2 2024.

Its largest position, NVO, represents 19.1% of the portfolio.

Compared with Q1 2024, the fund opened 10 new positions and exited 13.

Portfolio Metrics

Turnover
+18.1%
vs prior filed quarter
Top-10 Concentration
+62.2%
share of reported value
Largest Position
+19.1%
Novo Nordisk A S
New / Exited
10 / 13
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $262MQ4 ’22Q1 ’23: $271MQ2 ’23: $290MQ2 ’23Q3 ’23: $241MQ4 ’23: $344MQ4 ’23Q1 ’24: $498MQ2 ’24: $517MQ2 ’24Q3 ’24: $367MQ4 ’24: $280MQ4 ’24Q1 ’25: $395MQ2 ’25: $416MQ2 ’25Q3 ’25: $631MQ4 ’25: $706MQ4 ’25Q1 ’26: $499Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 50.3%Other: 25.6%ADR: 24.1%
  • Common Stock · 50.3% · $260M
  • Other · 25.6% · $133M
  • ADR · 24.1% · $125M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
NOVO-NORDISK A SNEW+310.0K310.0K+$44M$44M
ALNYALNYLAM PHARMACEUTICALS INCNEW+35.0K35.0K+$9M$9M
VIKING THERAPEUTICS INCNEW+150.0K150.0K+$8M$8M
INSMED INCNEW+110.0K110.0K+$7M$7M
ISIIONIS PHARMACEUTICALS INCNEW+62.5K62.5K+$3M$3M
TCE2CELLDEX THERAPEUTICS INC NEWNEW+75.3K75.3K+$3M$3M
SNDXSYNDAX PHARMACEUTICALS INCNEW+48.3K48.3K+$990,839$990,839
KROSKEROS THERAPEUTICS INCNEW+20.0K20.0K+$914,000$914,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

42 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1NVONOVO-NORDISK A Shistory →ADR19.09%$99M691.7K
2LLYELI LILLY & COhistory →COM16.20%$84M92.6K
3MRKMERCK & CO INChistory →COM10.59%$55M442.5K
4VKTXVIKING THERAPEUTICS INChistory →COM4.64%$24M453.0K
5AZNNASTRAZENECA PLChistory →SPONSORED ADR2.88%$15M190.8K
6ITCIEURINTRA-CELLULAR THERAPIES INChistory →COM2.87%$15M216.5K
7VRTXVERTEX PHARMACEUTICALS INChistory →COM1.71%$9M18.9K
8ALNYALNYLAM PHARMACEUTICALS INChistory →COM1.64%$9M35.0K
9AXSMAXSOME THERAPEUTICS INChistory →COM1.37%$7M87.8K
10ARGXARGENX SEhistory →SPONSORED ADR1.26%$7M15.1K
11NBIXNEUROCRINE BIOSCIENCES INChistory →COM1.20%$6M45.0K
12PCVXVAXCYTE INChistory →COM1.11%$6M76.3K
13PTGXPROTAGONIST THERAPEUTICS INCCOM0.83%$4M124.4K
14DYNDYNE THERAPEUTICS INCCOM0.82%$4M119.5K
15SLNOEURSOLENO THERAPEUTICS INCCOM0.74%$4M94.4K
16CRNXCRINETICS PHARMACEUTICALS INCOM0.74%$4M85.8K
17IM8NINSMED INCCOM PAR $.010.69%$4M53.4K
18OCULOCULAR THERAPEUTIX INCCOM0.66%$3M500.0K
19ISIIONIS PHARMACEUTICALS INCCOM0.58%$3M62.5K
20MERUS N VCOM0.57%$3M50.2K
21TCE2CELLDEX THERAPEUTICS INC NEWCOM NEW0.54%$3M75.3K
22APGEAPOGEE THERAPEUTICS INCCOM0.44%$2M58.4K
23SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.39%$2M53.9K
24IDYAIDEAYA BIOSCIENCES INCCOM0.37%$2M54.4K
25VRNAVERONA PHARMA PLCSPONSORED ADS0.37%$2M130.8K
26XENEXENON PHARMACEUTICALS INCCOM0.30%$2M40.0K
27MREOMEREO BIOPHARMA GROUP PLCSPON ADS0.29%$2M421.4K
28CHARLES RIV LABS INTL INCCOM0.28%$1M6.9K
29KURAKURA ONCOLOGY INCCOM0.23%$1M57.2K
30NEWAMSTERDAM PHARMA COMPANYORDINARY SHARES0.20%$1M54.3K
31ASCENDIS PHARMA A/SSPONSORED ADR0.20%$1M7.4K
32SLNSILENCE THERAPEUTICS PLCADS0.19%$997,04452.5K
33SNDXSYNDAX PHARMACEUTICALS INCCOM0.19%$990,83948.3K
34KROSKEROS THERAPEUTICS INCCOM0.18%$914,00020.0K
35CRBPCORBUS PHARMACEUTICALS HLDGSCOM NEW0.17%$905,00020.0K
36EYPTEYEPOINT PHARMACEUTICALS INCCOM NEW0.17%$883,050101.5K
37ANNXANNEXON INCCOM0.14%$722,677147.5K
38LRMRLARIMAR THERAPEUTICS INCCOM0.13%$656,05390.5K
39IRONDISC MEDICINE INCCOM0.12%$605,74113.4K
40PLRXPLIANT THERAPEUTICS INCCOM0.10%$537,50050.0K
41MDGLMADRIGAL PHARMACEUTICALS INCCOM0.08%$436,2091.6K
42SRPTSAREPTA THERAPEUTICS INCCOM0.08%$410,8002.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$499M50May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$706M55Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$631M51Nov 14, 2025RESTATEMENTchanges · EDGAR ↗
Q2 2025$416M37Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$395M38May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$280M37Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$367M45Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$517M46Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$498M49May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$344M31Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$241M27Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$290M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$271M36May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$262M25Feb 14, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.